GB1275, a first-in-class CD11b modulator: Rationale for immunotherapeutic combinations in solid tumors

Keyphrases

• Solid Tumors 100%
• Myeloid-derived Suppressor Cells 100%
• CD11b 100%
• Immunotherapeutics 100%
• First-in-class 100%
• Tumor Microenvironment 40%
• Immune Checkpoint Inhibitors 40%
• Tumor-associated Macrophages 40%
• Cell-Associated 40%
• Leukadherin-1 40%
• Cancer Therapy 20%
• Mouse Model 20%
• Clinical Trials 20%
• Cell Function 20%
• Breast Cancer 20%
• Prostate 20%
• Tumor Subtype 20%
• Breast 20%
• In Cancer 20%
• Therapeutic Approaches 20%
• Lung Cancer 20%
• Integrin Heterodimer 20%
• CD18 20%
• Mac-1 20%
• Cell Recruitment 20%
• Anticancer Therapy 20%
• Antitumor Immune Response 20%
• Neutrophil Migration 20%
• Pancreatic Adenocarcinoma 20%
• Advanced Solid Tumors 20%
• Inflammatory Conditions 20%
• Macrophage Migration 20%
• Drug-resistant Cancer 20%
• Response to Immunotherapy 20%
• Inhibitor Resistant 20%
• Immuno-oncology Therapy 20%
• Microsatellite Stable Colorectal Cancer 20%
• Salt Form 20%
• CD11b/CD18 Integrin 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Solid Malignant Neoplasm 100%
• Preclinical Study 100%
• Neoplasm 66%
• Malignant Neoplasm 66%
• Clinical Study 66%
• Tumor Microenvironment 66%
• CD18 Antigen 66%
• Immune Checkpoint Inhibitor 66%
• Clinical Trial 33%
• Mouse Model 33%
• Inflammation 33%
• Breast Cancer 33%
• Immunoglobulin 33%
• Lung Cancer 33%
• Immunotherapy 33%
• Integrin 33%
• Heterodimer 33%
• Pancreas Adenocarcinoma 33%
• Colorectal Carcinoma 33%
• Table Salt 33%